Recognition of the business case for ESG in pharma is soaring.
Geralyn Ritter
Advertisement
Geralyn Ritter is head of external affairs and ESG at Organon. In this role, she focuses on guiding and shaping how the company interacts with key stakeholders and the environment.
Articles by Geralyn Ritter
Nevertheless, it’s time to reassess how to leverage for greatest impact.
Drug access leads list of issues raised by pharma shareholders.
There is room to improve what good looks like across the industry.
Examining efforts to boost women representation on company boards.
The validity of ESG-driven investment and reporting in healthcare.
How principles of both can help companies navigate future storms.
Instead, incorporate ESG into your long-term business planning.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
Bob Mauch: Strengthening the Chain
3
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
4
mRNA Covid Vaccines Display Potential to Benefit Immunotherapy Cancer Drugs
5
